23 results about "Normal lung" patented technology

The invention discloses a formula for reducing phlegm and resolving masses, and a preparation method and application of freeze-dried powder of the formula for reducing phlegm and resolving masses, and belongs to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition inhibits triple negative breast cancer adhesion-metastasis by regulating an FAK / SRC pathway, and comprises the following components by weight: 10-20 g of poria cocos, 10-20 g of rhizoma bolbostemmae, 10-20 g of radix trichosanthis, 5-12 g of curcuma zedoary, 10-20 g of selfheal, 10-20 g of oyster (smashed and decocted first), and 5-12 g of uniflower swisscentaury root. In-vitro experiments show that HTSJF can inhibit TNBC cell invasion, migration and adhesion (P is less than 0.01) in a dose-dependent manner, and along with reduction of the phosphorylation level of an FAK / SRC pathway, it is prompted that HTSJF inhibits TNBC transfer by regulating the pathway. In-vivo experiments prove that the HTSJF can obviously inhibit the reduction of TNBC pulmonary metastasis focus (P is less than 0.05) and recover part of normal pulmonary alveolar structures, and the inhibition effect of the HTSJF on TNBC pulmonary metastasis is further proved.

The application provides an application of Buyang Huanwu Decoction in the preparation of a product for treating high altitude pulmonary injury of qi deficiency and blood stasis syndrome, and belongs to the technical field of medicines. After the prescription of the Buyang Huanwu Decoction is decocted with water, the decoction is used for treating high altitude pulmonary injury, can reduce pathological injury of lung tissues, reduce thickening of alveolar walls, make lung tissue structure clearer, and close to normal lung tissue morphology; meanwhile, the decoction can enhance exercise capacity, reduce asthenia symptoms of high altitude pulmonary injury of qi deficiency and blood stasis syndrome, and effectively treat high altitude pulmonary injury of qi deficiency and blood stasis syndrome.

This invention provides the application of N-Methylatanine in the preparation of fungal inhibitors, belonging to the field of antifungal drug technology. The N-Methylatanine of this invention is of natural origin and has low toxicity, exhibiting IC50 activity against normal human lung epithelial cells. 50 The concentration is >40 μM; it exhibits significant antibacterial effects. At a concentration of 100 μM, its inhibition rates against *Epidermophyton floccosum*, *Trichophyton rubrum*, and *Microsporum gypseum* reached 99.385±0.8%, 102.17±1.956%, and 100±0.115%, respectively. This invention provides a new approach for the treatment of fungal infections of the skin in humans and animals.

The invention discloses a benzacridine-3, 4-dicarboximide derivative as well as a preparation method and application thereof, the structure of the benzacridine-3, 4-dicarboximide derivative is shown as I-A, and n is equal to 1, 2, 3 or 4; the invention also discloses hydrochloride of the benzacridine-3, 4-dicarboximide derivative and a preparation method, all the compounds are subjected to CCK-8 experiments to investigate the cytotoxicity to 14 tumor cells and human normal lung embryo fibroblasts, and the compound 4 with the best activity is used for evaluating the cytotoxicity to SK-OV-3 ovarian cancer cell proliferation and invasion, the cytotoxicity to SK-OV-3 ovarian cancer cells, the cytotoxicity to human normal lung embryo fibroblasts and the cytotoxicity to SK-OV-3 ovarian cancer cells and the cytotoxicity to human normal lung embryo fibroblasts. And influence of migration capability. Subsequently, in-vivo anti-tumor activity of the compound 4 is found in a nude mouse xenotransplantation tumor experiment, and whether the compound has toxicity to mice or not is observed through pathological tissue slices under the administration treatment concentration. The invention has great value in discovery of new anti-tumor small molecule drugs and research and development of clinical drugs thereof.

The invention relates to the technical field of image analysis, in particular to a dynamic image registration method for pulmonary atelectasis focus volume change monitoring. Firstly, a CT image sequence of a respiratory cycle of a patient is collected; determining a breathing gray level change value based on the gray level difference of the pixel points between the images; dividing a local area according to the position of a pixel point and gray scale information; in a respiratory cycle, gas exchange in a pulmonary atelectasis area is limited, expansion capacity during inspiration is limited, a dynamic mode different from a normal lung tissue is formed, a first abnormal factor is determined by analyzing gray level change relation of pixel points in a local area and a global area and combining a respiratory gray level change value, and an abnormal area is screened out; due to pulmonary atelectasis, lung blood vessel displacement and gathering and lung volume reduction are caused, pixel point number difference characteristics are analyzed, and a second abnormal factor is determined by integrating local region blood vessels, a distribution relation and a breathing gray level change value; and finally, acquiring an adaptive enhancement factor based on the two, and performing adaptive sharpening enhancement on the image to improve the subsequent registration precision.

The present application relates to the field of biological extraction, and particularly relates to a kind of rattan tea selenium flavone III and its extraction method and application, the method includes boiling water extraction, macroporous resin purification, normal phase chromatography impurity removal, gel chromatography column chromatography impurity removal process, finally concentrated, spray drying treatment, as refined rattan tea selenium flavone III.The present application has simple process, low production cost, high rattan tea selenium polysaccharide IV compound yield and purity, the rattan tea selenium flavone III prepared has excellent anticancer activity to cancer cell, and also has no toxic side effects to normal lung epithelial cells, can be made into any dosage form acceptable in food and pharmacy.

The invention belongs to the technical field of biological medicine, and particularly relates to application of a CCL20 / CCR6 axis in bronchial pulmonary dysplasia. According to the application of the targeted CCL20 / CCR6 shaft in the aspect of preparing the medicine for treating bronchial pulmonary dysplasia, it is proved that CCL20 can cause damage to the normal pulmonary development process of newborn mice; and the neutralizing antibody of CCL20 or the antagonist of CCR6 can effectively improve the pulmonary alveoli development retardation of the BPD mouse induced by high oxygen exposure. The invention provides a new thought for preparing the medicine for treating the BPD, and a method for better treating the BPD is realized by applying the targeted CCL20 / CCR6 to the development process of the medicine related to the BPD; meanwhile, the selection field of medicines for treating BPD is widened, and contributions are made to the development of the technical field.

The invention relates to the technical field of biological medicine, in particular to a nucleic acid aptamer specifically combined with lung cancer cells and a screening method and application of the nucleic acid aptamer. A cell SELEX screening method is improved, lung cancer cells are used as positive screening cells, normal lung epithelial cells are used as negative screening cells for screening, the screening pressure is increased round by round, the screening efficiency is improved, and the nucleic acid aptamers Apt-1 and Apt-2 with high specificity and affinity for the lung cancer cells are obtained. As a novel molecular recognition probe, the nucleic acid aptamer disclosed by the invention has a wide application prospect in the aspects of early diagnosis, targeted therapy and the like of lung cancer.

The invention relates to the technical field of personal health risk assessment, in particular to a pulmonary nodule operation intervention assessment system based on image analysis. The method comprises the following steps: firstly, acquiring CT images of the lung of a patient in different preoperative periods and all nodules in each CT image; all nodules are classified and pre-classified into solid nodules, ground glass nodules and suspected partial solid nodules; further classifying all suspected partial solid nodules into partial solid nodules and ground glass nodules; and finally marking the operation risk according to the classification result of the nodules. According to the method, on the basis of the texture distinguishing features and the growth rule features of different types of nodules in the CT image, the misjudgment risk of the ground glass nodules and part of solid nodules growing on a normal lung tissue structure is reduced, so that the nodules are accurately classified, and the operation intervention necessity is accurately evaluated.

The sleeve type thoracic cavity puncture needle comprises a puncture needle body and a hollow tube, the puncture needle body is placed in the hollow tube, the upper end of the puncture needle body is fixedly connected with a connector, the interior of the connector is fixedly connected with a whistle tube, the whistle tube is aligned with the center of the puncture needle body, and a whistle hole is formed in the side surface of the whistle tube. A vibration piece is arranged on one side of the whistle hole and fixedly connected with the inner wall of the whistle pipe, the puncture needle is sleeved with a sleeve, the upper end of the sleeve is fixedly connected with a sleeve head, the sleeve head is buckled below the connector, the upper end of the hollow pipe is buckled with a pipe cap, the side surface of the pipe cap is fixedly connected with a hanging plate, and the upper end of the pipe cap is fixedly connected with a plastic plate. The problem that when an existing sleeve type thoracocentesis needle is used in an emergency, pneumothorax cannot be rapidly and accurately treated is solved, and meanwhile the situation that normal lungs and other organ tissues of a patient are injured due to the fact that medical staff puncture too deep in the operation process is avoided.

This invention relates to a method for extracting compound Alisma alkaloid A from Alisma plantago-aquatica and its application, effectively solving the problem of extracting Alisma alkaloids from Alisma plantago-aquatica and enabling its application in the preparation of drugs for treating lung cancer. This compound, Alisma alkaloid A, significantly reduces cell viability and Bcl2 expression, induces apoptosis and mitochondrial membrane depolarization in A549 lung cancer cells, and significantly increases the expression of Bax, Caspase3, and Caspase9, without affecting normal human lung epithelial cells BEAS-2B. It has the effect of inducing apoptosis in A549 cells through the mitochondrial apoptosis pathway, thus realizing the application of Alisma alkaloid A in the preparation of drugs for treating lung cancer. The method of this invention is scientifically sound, novel, unique, and easy to operate, effectively extracting compound Alisma alkaloid A from Alisma plantago-aquatica. This compound has the effect of inducing apoptosis in A549 cells through the mitochondrial apoptosis pathway, realizing the application of Alisma alkaloid A in the preparation of drugs for treating lung cancer, and expanding the medicinal and commercial value of Alisma plantago-aquatica.

The invention relates to application of ulinastatin and tetrandrine in preparation of a medicine for preventing and / or treating radiation-induced lung injury, and belongs to the technical field of biological medicine. The invention provides application of ulinastatin combined with tetrandrine in preparation of a medicine for preventing and / or treating radiation-induced lung injury. The ulinastatin and the tetrandrine are combined to be used as a medicine for treating mice suffering from radiation-induced lung injury, and the result shows that the ulinastatin and the tetrandrine have very good treatment and prevention effects on the radiation-induced lung injury, and the ulinastatin and the tetrandrine are non-toxic to lung cells; growth and development of normal lung cells cannot be inhibited, the treatment effect does not have dose dependence, the content of pro-inflammatory cytokines TNF-alpha and IL-6 can be remarkably reduced, the symptom of lung tissue inflammation can be relieved, and the survival rate of mice suffering from radiation-induced lung injury can be increased.

This invention discloses a stable human lung cell line overexpressing MLT1L, its construction method, and its applications. This invention belongs to the field of biomedicine, specifically relating to a stable human lung cell line overexpressing MLT1L, its construction method, and its applications. The substance promoting MLT1L expression of this invention can be applied to: (A1) improving the migration ability of normal lung cells; (A2) preparing products for improving the migration ability of normal lung cells; (A3) improving the invasive ability of normal lung cells; (A4) preparing products for improving the invasive ability of normal lung cells; wherein MLT1L is a long non-coding RNA with a nucleotide sequence as shown in SEQ ID No:1. This invention provides a method for constructing a stable human lung cell line overexpressing MLT1L, and overexpression of MLT1L-2034 can significantly increase the viability, proliferation, and invasive ability of Beas-2B cells.

The present application relates to the technical field of image analysis, in particular to a dynamic image registration method for monitoring volume change of atelectasis lesion. First, a CT image sequence of a patient in one respiratory cycle is collected; a respiratory gray level change value is determined based on the gray level difference of the pixels between images; then, local areas are divided according to the position and gray level information of the pixels; in the respiratory cycle, the gas exchange of the atelectasis area is limited, the expansion capacity is limited during inhalation, and a dynamic mode different from normal lung tissue is formed; by analyzing the gray level change relationship of the pixels in local and global areas, and combining the respiratory gray level change value, a first abnormal factor is determined to screen out abnormal areas; because the atelectasis causes the displacement and gathering of pulmonary blood vessels and the reduction of lung volume, the difference characteristics of the number of pixels are analyzed, and the second abnormal factor is determined by comprehensively considering the blood vessels in the local area, the distribution relationship and the respiratory gray level change value; finally, an adaptive enhancement factor is obtained based on the two factors, the image is adaptively sharpened and enhanced, and the subsequent registration accuracy is improved.

The invention discloses an early warning evaluation method based on canceration caused by pulmonary nodule immune microenvironment imbalance, which comprises the following steps: S1, acquiring autoantibody detection data of normal, pulmonary nodule and lung cancer people from a database, and establishing a pulmonary nodule canceration data set Panne l containing 159 autoantibodies as risk early warning factors of pulmonary nodule canceration; s2, preparing a lung cancer risk factor Panne l protein chip according to the Panne l data, wherein the lung cancer risk factor Panne l protein chip comprises antigen proteins of 159 lung cancer related autoantibodies; s3, using a Panne l protein chip to detect the serum of the crowd; and S4, according to the detection data, establishing a risk early warning model of pulmonary nodule canceration for the analysis and early warning of the lung cancer occurrence risk of the crowd (mainly aiming at the pulmonary nodule crowd). According to the method, the cancer related autoantibodies are systematically detected through a protein chip method for people with high detection rate of pulmonary nodules in China, and the method is used for early warning of the occurrence risk of pulmonary nodule immune abnormality canceration of people.

The invention discloses a non-small cell lung cancer specific promoter gene element and a screening method and application thereof, and belongs to the technical field of gene engineering. A non-small cell lung cancer specific promoter gene element to be screened is obtained through a biological database, then the non-small cell lung cancer specific promoter gene element to be screened, a reporter gene and an expression vector are fused, and a non-small cell lung cancer specific promoter region in the expression vector regulates downstream reporter gene expression. The non-small cell lung cancer specific promoter gene element KRT19P4 is screened by taking the biological activity of a reporter gene as an activity evaluation standard of a non-small cell lung cancer biomarker promoter, and the sequence is shown as SEQ ID NO.16. A bioluminescence test proves that the KRT19P4 promoter gene element can enable luciferase reporter genes in normal lung cells and non-small cell lung cancer cells to generate differential enzyme activity intensity.

The present invention relates to a lung ex vivo model, a construction method therefor, and a use thereof. The lung ex vivo model provided by the present invention uses lung organoids instead of traditional cell lines to construct the lung ex vivo model. The construction method provided by the present invention involves sequentially seeding lung organoids, endothelial cells, macrophages, and, optionally, immune cells. A normal lung ex vivo model is obtained by first culturing in a liquid-liquid mode, followed by culturing in an air-liquid mode. On this basis, a lung fibrosis model can optionally be obtained by treating the lung ex vivo model by using a lung fibrosis inducer.

The invention relates to a super-selection lung recruitment system and a recruitment path generation method thereof. The system comprises an EIT monitoring subsystem, a CT image acquisition subsystem, a multi-modal image fusion subsystem, a control subsystem and a lung recruitment subsystem. The EIT monitoring subsystem acquires and processes lung electrical impedance data in real time and generates an EIT image marking a collapse area, the CT image acquisition subsystem acquires chest CT scanning data, the multi-modal image fusion subsystem calculates and outputs an optimal path by combining the two types of data, the control subsystem receives the optimal path data and converts the optimal path data into a control instruction, and the control subsystem controls the control instruction. A data adjusting instruction is fed back in real time according to the EIT monitoring subsystem, and finally the lung recruitment subsystem reaches the lung collapse area along the optimal path according to the instruction to complete recruitment. Compared with the prior art, the method has the advantages that accurate positioning and super-selection re-expanding of the lung collapse area are achieved, the re-expanding accuracy and efficiency are improved, interference on normal lung tissue is reduced, and the operation risk is reduced.

This invention discloses the preparation and application of organoselenium flavonoids with high antioxidant activity and low toxicity, relating to the field of functional food technology. The method of this invention includes pulverizing selenium-enriched vine tea, selenium-enriched kudzu root, selenium-enriched gastrodia elata, and selenium-enriched papaya, then mixing them according to a specified ratio, low-temperature reflux extraction, hollow fiber ultrafiltration membrane purification, activated carbon depigmentation, reversed-phase silica gel degreasing and polysaccharide removal, gel chromatography purification, and freeze-drying or spray drying. This invention uses a novel food resource combination of vine tea, kudzu root, gastrodia elata, and papaya—medicinal and edible herbs—as raw materials to extract organoselenium flavonoids with a high yield. Furthermore, the extracted selenium flavonoids exhibit extremely strong DPPH free radical scavenging activity and show no toxic side effects on normal human renal tubular epithelial cells (HKC) and normal lung epithelial cells (BEAS-2B). Therefore, the content of this invention is of great significance to the development of the field of antioxidant functional foods.

The invention provides a pulmonary surfactant protein D antibody or an antigen binding fragment, the antibody is a monoclonal antibody generated by a hybridoma, and the antigen binding fragment is an antigen binding fragment of the monoclonal antibody generated by the hybridoma. The method can be used for determining whether a subject has a normal pulmonary surfactant protein D level or not, determining whether the subject has potential lung injury or not and determining disease progression of the subject, and has important clinical significance.

The invention provides application of combination of ambroxol and ferulic acid in preparation of a preparation for preventing and / or treating radiation-induced lung injury, and belongs to the technical field of biological medicine. The ambroxol and the ferulic acid are combined for use, so that a good prevention and treatment effect on radiation-induced lung injury caused by ionizing radiation can be achieved, early-stage acute radiation pneumonitis can be inhibited, a long-term lung function can be improved, and lung fibrosis can be blocked. On the premise of remarkably reducing the administration dosage of ambroxol and ferulic acid, the survival rate of a radiation-induced lung injury model mouse is increased by 55%, expression of TNF-alpha and TGF-beta1 is more effectively inhibited, no toxic or side effect is generated on normal alveolar epithelial cells, and the pharmaceutical composition is suitable for clinical application. The traditional Chinese medicine composition has the advantages of small dosage, excellent prevention and / or treatment effect, no toxic or side effect, no dose dependence and the like.

The invention discloses a medicine prepared from rare ginsenoside Rg5 and used for treating lung malignant tumors and a preparation method of the medicine, and relates to the technical field of medical drugs, and the medicine is prepared from the following components in parts by weight: 10-20 parts of rare ginsenoside Rg5, 10-15 parts of pH-liposome, 8-12 parts of curcumin-polyethylene glycol, 5-8 parts of ganoderan and 5-10 parts of beta-cyclodextrin. The pH-lipidosome is used as a carrier, and the carrier of the pH-lipidosome can adapt to the characteristics of a lung tumor microenvironment, so that rare ginsenoside Rg5, curcumin-polyethylene glycol and ganoderma lucidum polysaccharide can be guided to accurately tend to lung tumor tissues, non-specific distribution of drugs in normal lung tissues and other organs is reduced, and the curative effect is improved. The active ingredients are prevented from being wasted or degraded at non-target parts, so that the effect of efficiently enriching the medicine in lung tumor tissues is achieved, the targeting effect of the medicine on lung malignant tumors is enhanced, the targeting property of the medicine is improved, and the targeting inhibition effect of the medicine on lung cancer is improved.

The invention discloses a near-infrared first-zone luminescence gold nanocluster synthesized based on a sodium borohydride reduction method and application of the near-infrared first-zone luminescence gold nanocluster to early noninvasive imaging and detection of lung cancer through tracheal delivery. The surface of the gold nanocluster is modified with glutathione, the core size is 1.2 + / -0.2 nm, the gold nanocluster has the maximum emission peak at 800 nm, and the gold nanocluster can be used for biological fluorescence imaging and is high in biological safety. The nano-cluster with the surface modified with glutathione is delivered to an airway system in a tracheal delivery mode, and accurate detection is achieved by means of the remarkable difference of the residence time of the nano-particles by lung cancer tissue and normal tissue. Experiments show that nanoclusters in normal lung tissue metabolize quickly, and light-emitting signals are short; in the in-situ lung cancer tissue, the residence time is prolonged, the signal is continuously enhanced, the disease progress is quantified through the residence time difference, and noninvasive detection is performed on the early-stage lung cancer. Compared with traditional biopsy, the method has the advantages of noninvasive and real-time imaging, and a new solution is provided for early screening of lung cancer.